PD57-12 WHICH PATIENTS WITH OLIGOMETASTATIC PROSTATE CANCER SHOULD BE CONSIDERED FOR CYTOREDUCTIVE RADICAL PROSTATECTOMY AS PART OF A MULTIMODAL TREATMENT? RESULTS FROM A LARGE, MULTI-INSTITUTIONAL COLLABORATION

Simone Scuderi,Elio Mazzone,Axel Heidenreich,Giorgio Gandaglia,David G. Pfister,Shahrok Shariat,Bernhard Grubmüller,Giuseppe Fallara,Nicola Fossati,Antony Pellegrino,R. Jeffrey Karnes,Vito Cucchiara,Daniele Robesti,Carlo Andrea Bravi,Riccardo Leni,Donato Cannoletta,Andrea Gallina,Nazareno Suardi,Armando Stabile,Marco Moschini,Andrea Necchi,Francesco Montorsi,Alberto Briganti

PD57-12 WHICH PATIENTS WITH OLIGOMETASTATIC PROSTATE CANCER SHOULD BE CONSIDERED FOR CYTOREDUCTIVE RADICAL PROSTATECTOMY AS PART OF A MULTIMODAL TREATMENT? RESULTS FROM A LARGE, MULTI-INSTITUTIONAL COLLABORATION

2021

INTRODUCTION AND OBJECTIVE:Cytoreductive radical prostatectomy (cRP) might be an option in oligometastatic prostate cancer (PCa). However, no preoperative risk tool is available to select candidate...

Keywords:

multimodal treatment
Prostatectomy
Oncology
Prostate cancer
preoperative risk
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations